Mets Day 1040 I’m in the nivolumab-a lot competitive cohort

Mets Day 1040

Image source:×572.jpg

I acquired an email from the medical trial nurse at Johns Hopkins, advising me that, for the medical trial in which I am enrolled (A Phase zero.5, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors), I have been randomized into Arm N. This implies that I will only receive the Nivolumab (Opdivo) anti-PD-1 drug, and will no longer get ipilimumab. The infusions can also be each varied week. I will get 3mg of nivolumab per kilogram of my body weight. I get my first infusion tomorrow morning.

I'm very cheerful about this news. I very plenty essential to get a PD-1 or PD-L1 drug and was once no longer that eager to get ipilimumab along side it. Ipilimumab has more side effects, and has no longer been shown to have an fabulous have an effect on on metastatic bladder cancer. I'm hopeful that there is quite few side effects from nivolumab only.

I will ought to juggle some of my journey plans around the schedule, however. In early March, Spencer and I are going to Utah to talk about with Rose and her father and mother, and depending upon how I feel, can be do some snowboarding. I will no longer have to make any changes to that journey, it appears. But in late March, Jennifer, Kirsten, and Garrett and I are booked to fly to Florida to talk about with my father and mother over spring break. I'll have to push back my departure by two days to get my infusion. And in May, I am making plans to fly out to Utah for my niece's wedding, and the birth of grandbaby #2. I'll have to shorten that journey. That's why I fly on Southwest – no cancellation fees and really appropriate rebooking. It turns out that the new flight dates are even more cost-mighty than the tickets I had already purchased, so happy day!

Today I saw an abstract of a refreshing article about the management of metastatic bladder cancer from a French medical magazine, La Revue du Praticien. The abstract bluntly summarizes the modern fame of therapy of metastatic bladder cancer:

The management of victims with metastatic bladder cancer is specially founded on cytotoxic chemotherapy. The reference molecule is cisplatin. In 2014, first-line regimens incorporate gemcitabine and cisplatin (GC protocol) or methotrexate, vinblastine, and cisplatin doxorubicin (MVAC protocol). When cisplatin is contra-indicated, an alternate platinum salt, carboplatin, is used in mixture with gemcitabine. Vinflunine is the only molecule to have obtained a advertising and marketing approval for victims who failed first-line chemotherapy which come with a platinum salt. The effortless prognosis of victims continues to be dismal, on account that the median effortless survival is 12 to fourteen months for victims being treated with cisplatin, when it can be plenty no longer up to 1 year for victims receiving carboplatin. The identification of new mighty tablets is a primary challenge for the arrival years.
I'm two months away from my third anniversary of the discovery that my bladder cancer had metastasized, so I am method past the median survival point. I'm aware than it's been more than two decades on account that the FDA has approved a new drug for the therapy of bladder cancer, and I'm hopeful that nivolumab is possibly probably the most "mighty new tablets" that the article says can also be a "primary challenge" to name.

Leave a Reply

Your email address will not be published. Required fields are marked *